Type 2 Diabetes
Conditions
Interventions
Bena:Benaglutide
Bena_Sita:Benaglutide and sitagliptin
Sponsors
Fuwai Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Participants signed informed consent; 2. Aged from 18 to 70 (include); 3. Diagnosed type 2 diabetes (criteria of WHO, 1999); 4. Body mass index is above 21 and no more than 40.0 kg/m2; 5. HbA1c is above 8% and no more than 11%; 6. Before the scranning, participant was treated with metformin in a dose more than 1000mg per day and for more than 3 months; 7. Judged by investigator, participant can and is eager to obey: 8. According to investigation, insist to treatment during the whole study; 9. Participate the interview and follow-up by telephone; 10. Avoid to pregnant.
Exclusion criteria
Exclusion criteria: 1) Allergic to benaglutide, sitagliptin, or any component or contraindications or intolerance 2) Use of drug weight loss before screening 3) The subject experienced more than 3 severe hypoglycemias within 6 months prior to screening. 4) Use insulin and insulin sensitizer within 3 months before screening 5) abnormal liver function, alanine aminotransferase (ALT) is greater than the upper limit of 2 times 6) Chronic kidney injury, creatinine (Cr) >133µmol/L 7) Patients with severe heart disease, such as heart failure, unstable angina, myocardial infarction 8) Patients with vestibular diseases 9) Patients with malignant tumors and active tuberculosis 10) Those taking glucocorticoids (excluding topical or inhaled medications)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c;blood glucose; | — |
Countries
China
Contacts
Public ContactYanyan Chen
Fuwai Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed